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Summary
 
Classical class I major histocompatibility complex (MHC) molecules, as well as the nonclassical
class I histocompatibility leukocyte antigen (HLA)-E molecule, can negatively regulate natural
killer (NK) cell cytotoxicity through engagement of NK inhibitory receptors. We show that
expression of murine (m)CD1.1, a nonpolymorphic nonclassical MHC class I–like molecule
encoded outside the MHC, protects NK-sensitive RMA/S target cells from adherent lym-
phokine-activated killer cell (A-LAK) cytotoxicity. Passage of effector cells in recombinant in-
terleukin (rIL)-2 enhanced protection by mCD1.1, suggesting an expansion of relevant A-LAK
population(s) or modulation of A-LAK receptor expression. Murine CD1.1 conferred protection
from lysis by rIL-2–activated spleen cells of recombination activating gene (Rag)-1
 
2
 
/
 
2
 
 mice,
which lack B and T cells, demonstrating that mCD1.1 can protect RMA/S cells from lysis by
NK cells. An antibody specific for mCD1.1 partially restored A-LAK lysis of RMA/S.CD1.1
transfectants, indicating that cell surface mCD1.1 can confer protection from lysis; therefore,
mCD1.1 possibly acts through interaction with an NK inhibitory receptor. CD1.1 is by far the
most divergent class I molecule capable of regulating NK cell activity. Finally, mCD1.1 expres-
sion rendered RMA/S cells resistant to lysis by A-LAK of multiple mouse strains. The con-
served structure of mCD1.1 and pattern of mCD1.1 resistance from A-LAK lysis suggest that
mCD1.1 may be a ligand for a conserved NK inhibitory receptor.
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N
 
atural killer (NK) cells can mediate innate resistance
against microbes and tumor challenges (1, 2). They
can carry out these functions by secreting cytokines, partic-
ularly IFN-
 
g
 
, and by lysing virally infected or transformed
cells, without prior sensitization (3, 4). NK cells do not ex-
press Igs or TCRs, yet they are able to discriminate self
from non-self. According to the “missing self” hypothesis
of Kärre and colleagues (5, 6), NK cell cytotoxic activity is
regulated by self–MHC class I molecule expression, such
that a tumor with downregulated MHC expression can be
highly susceptible to NK cell lysis (7, 8). This model is sup-
ported by the identification of various class I MHC–specific
inhibitory receptors expressed by NK cells of both humans
and mice (9–11). For example, Ly-49A, a lectin-like NK
inhibitory receptor expressed in mice, recognizes H-2D
 
d
 
and D
 
k
 
, and downregulates Ly-49A
 
1
 
 NK cell cytotoxic ac-
tivity (12–14). The human p58 and p70 killer cell inhibi-
tory receptors (KIRs)
 
1
 
 are known to interact with various
alleles of HLA-B and HLA-C, with a similar functional
outcome (15, 16). Therefore, it is well established that clas-
sical class I MHC molecules can regulate NK cell activity.
Unlike classical class I MHC genes, the nonclassical class
I MHC genes, such as those encoded by the murine 
 
T
 
, 
 
Q
 
,
and 
 
M
 
 regions, exhibit little or no polymorphism (17). In
general, they also have a more restricted expression pattern
than classical class I MHC products. Although the function
of some of these nonclassical class I molecules is unknown,
there is evidence suggesting that some of them have spe-
 
1
 
Abbreviations used in this paper:
 
 A-LAK, adherent lymphokine-activated
killer cell; KIR, killer cell inhibitory receptor; m, murine; NA-LAK,
nonadherent lymphokine-activated killer cell; NKT cells, natural T cells;
NP, nucleoprotein; Rag, recombination activating gene; TAP, trans-
porter of antigen presentation. 
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cialized antigen-presenting functions (17, 18). CD1, a non-
classical MHC class I–like molecule, is encoded outside the
MHC region (17, 18). Although classified as a class I mole-
cule, CD1 molecules share only 5–15% sequence identity
with classical class I molecules in the 
 
a
 
1 and 
 
a
 
2 domains.
In the more conserved 
 
a
 
3 extracellular domain, the se-
quence identity is 
 
z
 
30%. In fact, CD1 molecules are about
as closely related to MHC class II as they are to MHC class
I molecules (19), suggesting that they diverged relatively
early in evolution from the MHC-encoded antigen-pre-
senting molecules. The CD1 family is itself quite divergent,
and based on amino acid sequence homology, human CD1
molecules can be classified into groups 1 and 2 (20). The
former group includes CD1a–c and e, whereas CD1d be-
longs to the latter group (17, 18, 20). In mice, CD1 is en-
coded by two closely related genes, murine (m)CD1.1 and
mCD1.2, that are most homologous to human CD1d (17,
18, 20). Like classical MHC class I molecules, CD1 expres-
sion is mostly 
 
b
 
2
 
-microglobulin dependent (21, 22). The
available x-ray crystallographic data show that mCD1.1
cocrystalizes with 
 
b
 
2
 
-microglobulin and adopts a structure
generally resembling classical class I and class II antigen-
presenting molecules, although the antigen binding groove
is more narrow and hydrophobic (23). The CD1 molecule
is a ligand for the TCR expressed by a subset of T cells ex-
pressing NK markers, termed natural T (NKT) cells (24).
These T cells secrete large amounts of IL-4 and IFN-
 
g
 
 upon
activation by anti-CD3 mAbs (25). Unlike classical MHC
class I molecules, CD1 antigen presentation is transporter
of antigen presentation (TAP) independent (21, 22). Al-
though mCD1.1 can present peptides with a hydrophobic
binding motif (26), this unusual TAP-independent behav-
ior is explained in part by the observation that CD1 is
also capable of presenting glycosylceramides and microbial
lipoglycan antigens to NKT cells (27–30).
Recently, the human nonclassical MHC class I molecule
HLA-E has been demonstrated to inhibit NK cell cytotoxic
activity through interaction with the CD94/NKG2A NK
inhibitory receptor (31, 32). In addition, HLA-G is able to
interact with an Ig-like inhibitory receptor, ILT4 (33).
These results raise the possibility that other nonclassical
class I MHC products might regulate NK cell activity. In
this report, we present evidence that mCD1.1 negatively
regulates murine NK cell cytotoxic activity. This is the first
report to show that a class I molecule encoded outside the
MHC region, can regulate NK cell function. mCD1.1
is now the most divergent antigen-presenting molecule
known to regulate NK cell function. Our data further sug-
gest the possible existence of a conserved receptor(s) which
recognizes mCD1.1.
 
Materials and Methods
 
Mice.
 
Female C57BL/6 (B6, H-2
 
b
 
) mice were obtained from
The Jackson Laboratory and Charles River Laboratories. Female
CBA/J (H-2
 
k
 
), NZB/BinJ (H-2
 
d
 
), and 129 
 
3 
 
B6 recombination
activating gene (Rag)-1
 
2
 
/
 
2
 
 (H-2
 
b
 
) mice were purchased from
 
The Jackson Laboratory. All mice were 8–12 wk of age, except
the NZB/BinJ mice, which were 9 mo of age.
 
mAbs.
 
The 1B1 (rat IgG
 
2b
 
) mAb, anti-mCD1, has been de-
scribed previously (34). M1/89.18.7.HK (rat IgG
 
2b
 
), the anti-
CD45 hybridoma, was obtained from American Type Culture
Collection. Tissue culture supernatants were prepared from the
1B1 and M1/89.18.7.HK hybridomas incubated in protein-
free hybridoma medium. 1B1 was purified using a protein G–seph-
arose 4B affinity column and dialyzed against PBS. The M1/
89.18.7.HK mAb was obtained from the M1/89.18.7.HK hybri-
doma supernatant by ammonium sulfate precipitation and dialysis
against PBS. FITC-conjugated goat anti–rat IgG was purchased
from Jackson ImmunoResearch Laboratories.
 
Tumor Cell Lines.
 
The NK-sensitive target Yac-1 T lym-
phoma was obtained from American Type Culture Collection.
The TAP-2–deficient RMA/S T lymphoma and the RMA/
S.CD1.1 transfectant have been described previously (22). The
RMA T lymphoma was a gift from Dr. Jefferies (University of
British Columbia, Vancouver, Canada). All of the tumor cell
lines were maintained in RPMI, with 5% heat-inactivated FCS,
20 mM Hepes, 2 mM 
 
l
 
-glutamine, 100 U/ml penicillin, and 100
 
m
 
g/ml streptomycin. For RMA/S.CD1.1, 100 
 
m
 
g/ml of G418
was also added to the culture.
 
Cloned CTL.
 
Clone 3/4 is a C57BL/6-derived CTL clone
specific for D
 
b
 
 and the influenza nucleoprotein peptide (NP)
(360–380) of the A/PR/8/34 influenza virus (35). Clone 3/4 was
maintained as described previously (35).
 
Generation of Poly I:C–activated Killer Cells.
 
Each C57BL/6
mouse was injected with 200 
 
m
 
g i.p. of poly I:C. After 18 h,
spleen cells were harvested from these mice and RBCs were re-
moved by lysing with 0.14 M NH
 
4
 
Cl. Adherent cells were re-
moved by culturing the splenocytes on tissue culture–treated
plates for 1 h at a density of 5 
 
3 
 
10
 
6
 
 cells/ml at 37
 
8
 
C. The non-
adherent cells were then used as effector cells in 
 
51
 
Cr-release as-
says.
 
Generation of Adherent Lymphokine-activated Killer Cells.
 
Ad-
herent lymphokine-activated killer cells (A-LAKs) from different
mouse strains were generated as described (36). In brief, adherent
cells from the total splenocyte population were removed by cul-
turing them on tissue culture–treated plates for 1 h. Nonadherent
cells were then harvested and passaged through a nylon wool col-
umn to remove B cells. The nylon wool nonadherent cells, at a
density of 10
 
6
 
 cells/ml, were cultured in RPMI/10% FCS sup-
plemented with sodium pyruvate, nonessential amino acids, 5 
 
3
 
10
 
2
 
5
 
 M 2-ME (hereafter referred to as complete medium) and
with 800 U/ml of recombinant human IL-2 (rIL-2) expressed in
and isolated from 
 
Escherichia coli
 
. After 3 d of culture, the nonad-
herent (NA)-LAKs were removed, and the A-LAKs were then
maintained in complete medium with 800 U/ml of rIL-2 for an
additional 4 d. Operationally, these A-LAKs are referred to as day
3 A-LAKs. The NA-LAKs were recultured in the presence of the
same concentration of rIL-2, and the A-LAKs generated from this
culturing condition on day 4 are referred to as day 4 A-LAKs. After
1 d of culture, the NA-LAKs generated from the day 4 A-LAKs
were removed and recultured as before, and are referred to as day
5 A-LAKs. The process was repeated until day 7. Like day 3
A-LAKs, day 4, 5, and 6 A-LAKs were cultured until day 7 in
rIL-2 after their selection. In all instances, only the A-LAKs were
used as effector cells in 
 
51
 
Cr-release assays. The 129 
 
3 
 
B6 Rag-
1
 
2
 
/
 
2
 
 A-LAKs were obtained by culturing the RBC-depleted
splenocytes with 800 U/ml of rIL-2 for 6 d. The NA-LAKs were
then removed, and the A-LAKs were cultured for an additional
6 d in the presence of rIL-2. 
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Cytotoxic Assay.
 
Targets cells were labeled with 100 
 
m
 
Ci of
Na
 
51
 
CrO
 
4
 
 for 1 h. After extensive washing, 10
 
4
 
 
 
51
 
Cr-labeled tar-
get cells were incubated with poly I:C–activated killer cells or
A-LAKs at various E/T ratios for 4–5 h at 37
 
8
 
C in a V-bottomed
microtiter plate in triplicate. For killing by CTL clone 3/4,
RMA/S and RMA/S.CD1.1 were incubated at 26
 
8
 
C overnight
to induce higher expression of D
 
b
 
. The cells were then labeled
with 
 
51
 
Cr and pulsed with 400 
 
m
 
g/ml of NP peptide, YASNEN-
METM, at 37
 
8
 
C for 1 h before the cytotoxic assay. In all in-
stances, the percentage of lysis was determined as [(experimental
release 
 
2 
 
spontaneous release)/(maximum release 
 
2 
 
spontaneous
release)] 
 
3 
 
100. Unless stated otherwise, all cytotoxic assays in
this report were performed in triplicate.
 
mAb Blocking Assay.
 
The 
 
51
 
Cr-labeled targets were incubated
with 40 
 
m
 
g/ml of M1/89.18.7.HK or 1B1 for 30 min at room
temperature. The effector cells were then added to the wells di-
luting the mAb concentration to 20 
 
m
 
g/ml. The 
 
51
 
Cr-release as-
says were carried out in the presence of these mAbs for 4–5 h at
37
 
8
 
C.
 
Results
 
mCD1.1 Expression Inhibits A-LAK Cytotoxic Activity.
 
We were interested in examining the ability of mCD1.1 to
inhibit NK cytotoxic activity. To address this issue, we
took advantage of the fact that mCD1.1 expression is TAP
independent (21, 22), and thus mCD1.1 can be expressed
at the cell surface by the NK-sensitive TAP-2–deficient T
lymphoma cell line, RMA/S (22). As detected by the
mCD1.1-specific mAb 1B1, RMA/S expresses high levels
of mCD1.1 upon transfection compared with that of the
untransfected control (22). Since classical class I MHC ex-
pression requires the presence of functional TAP, this sys-
tem enables us to assess the potential protective effect of
mCD1.1 without the complication of inhibition also medi-
ated by the endogenous classical class I MHC products D
 
b
 
and K
 
b
 
.
We first carried out in vitro killing assays of RMA/S and
RMA/S.CD1.1, using poly I:C–activated B6 NK cells. As
expected, the class I MHC–deficient cell line, RMA/S, is
susceptible to NK cell lysis. However, a modest but repro-
ducible reduction in lysis of the RMA/S.CD1.1 transfec-
tant was detected at higher E/T ratios where cytotoxicity is
substantial, but not apparently at plateau, and can be readily
compared between the experimental groups (Fig. 1). This
suggested that mCD1.1 is able to inhibit NK cell cytotoxic
activity, but perhaps only a small fraction of the total poly
I:C–activated NK cell population is negatively regulated by
mCD1.1. Therefore, we performed cytolytic assays using
B6 A-LAKs to test the possibility that mCD1.1-regulated
killer cells could be expanded when cultured in the pres-
ence of rIL-2. The RMA/S cell line and two independent
RMA/S.CD1.1 transfectant clones were compared for
their sensitivity to lysis by nylon wool nonadherent B6
spleen cells that become plate adherent in succeeding days
of culture in rIL-2. RMA/S and the two RMA/S.CD1.1
transfectants were susceptible to lysis by the day 3 and 4
A-LAKs. Nevertheless, a moderate reduction in lysis by
these A-LAKs of both RMA/S.CD1.1 transfectants relative
to RMA/S was detected (Fig. 2). Interestingly, day 5 and 6
A-LAK cytotoxic activities against the RMA/S.CD1 trans-
fectants was substantially reduced relative to the highly sen-
sitive RMA/S target cell (Fig. 2). Resistance to lysis of the
Figure 1. mCD1.1 partially
inhibits the cytotoxic activity of
poly I:C–activated B6 NK cells.
Mice were injected with 200 mg
of poly I:C, and 18 h later the
spleen cells were harvested and
the plastic nonadherent spleen
cells were used as effector cells
for the lysis of 51Cr-labeled
RMA/S and RMA/S.CD1.1.
Each E/T ratio was used for trip-
licate determinations, and the re-
sults are expressed as means 6
SD. Spontaneous release values
were  ,10.3%. Similar results
were obtained in three separate
experiments.
Figure 2. The extent of mCD1.1 inhibition of B6 A-LAK cytotoxic
activity is affected by passage of LAKs. B6 A-LAKs were generated
by daily transfer after day 3 of the NA-LAKs to new flasks. Lysis of two
independent RMA/S.CD1.1 transfectant clones, RMA/S.CD1.1A and
RMA/S.CD1.1B, was compared with RMA-S cells. The 51Cr-labeled
targets were incubated with the A-LAKs from all groups obtained at day 7
of culture at different E/T ratios for 4 h at 378C. Each E/T ratio was used
for triplicate determinations, and results are shown as the means 6 SD.
All spontaneous release values were ,10.2%. Similar results were ob-
tained in six separate experiments. 
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RMA/S.CD1.1 transfectants was found to be enhanced
despite an increase of lysis observed for the untransfected
RMA/S target cell at lower E/T ratios by the day 5 and
6 A-LAKs (Fig. 2). The two CD1 transfectants, RMA/
S.CD1.1A and RMA/S.CD1.1B, express comparable den-
sities of CD1.1 (data not shown) and show a similar level of
resistance to A-LAK lysis, indicating that the results are re-
producible, occurring with more than one CD1.1 transfec-
tant. Subsequent experiments described in this report were
carried out with the RMA/S.CD1.1A transfectant, nomi-
nally referred to as RMA/S.CD1.1. Taken together, the
preceding results obtained with IL-2–activated A-LAKs
strongly argue that mCD1.1, like classical class I MHC,
may negatively regulate A-LAK cytotoxic activity. In agree-
ment with the poly I:C data, it seems that a small propor-
tion of the initial A-LAK population may be negatively
regulated by mCD1.1, which possibly can be expanded by
passage and culture in the presence of rIL-2.
The A-LAK–mediated cytotoxicity data demonstrated
the protective effect of mCD1.1 expression on RMA/S
susceptibility to A-LAK lysis. However, it did not show its
target protection/A-LAK inhibitory efficiency compared
with that of classical class I MHC. To address this issue, the
level of RMA/S.CD1.1 lysis by pooled day 5 and 6 B6
A-LAKs was compared with that of RMA (from which the
class I MHC–deficient RMA/S is derived). The class I
MHC–positive cell line, RMA, is resistant to day 5 and 6
A-LAK lysis (Fig. 3) and A-LAKs selected at several other
time points of culture in rIL-2 (data not shown), whereas
RMA/S is lysed to a similar degree as the NK cell–sensitive
T lymphoma, Yac-1. In contrast, RMA/S.CD1.1 is as re-
sistant to day 5 and 6 A-LAK cytotoxic activity as RMA
(Fig. 3). Thus, these results suggest that mCD1.1 can nega-
tively regulate NK cell cytotoxicity to the same extent as
classical class I MHC. Since the day 5 and 6 B6 A-LAKs
failed to lyse both RMA and RMA/S.CD1.1, this further
suggests that these A-LAKs can be negatively regulated by
both classical MHC class I molecules and mCD1.1.
It might be argued that upon mCD1.1 transfection,
RMA/S simply becomes resistant to cell-mediated cyto-
toxicity, independent of killer cell recognition events. How-
ever, this interpretation is not supported by the observation
that both RMA/S and RMA/S.CD1.1 were lysed effi-
ciently by A-LAKs generated from early time points (Fig.
 
2). In addition, after induction of higher classical class I
MHC expression at 26°C and incubation with peptide an-
tigen, both RMA/S and the RMA/S.CD1.1 transfectant
were lysed to a similarly high level by the influenza NP–
specific, D
 
b
 
-restricted CTL clone 3/4 (Fig. 4). For instance,
only after pulsing with D
 
b
 
-specific influenza NP peptide,
but not in the absence of peptide or in the presence of the
K
 
b
 
-binding OVA peptide, SIINFEKL (data not shown),
can lysis be detected. This indicated that intracellular apop-
totic pathways remain intact upon mCD1.1 transfection.
Thus, RMA/S.CD1.1 is not intrinsically resistant to cell-
mediated lysis.
 
NK Cell Cytotoxic Activity Is Inhibited by mCD1.1 Expres-
sion.
 
Our results obtained with A-LAKs do not directly
assess whether mCD1.1 inhibits the cytotoxic activity of
NK cells or some other cell types. Therefore, we directly
addressed this issue by using effector cells derived from B6 
 
3
 
129 Rag-1
 
2
 
/
 
2
 
 mice. Since the recombination activating
gene, Rag-1, is critical in V(D)J recombination in both B
and T cells, Rag-1
 
2
 
/
 
2
 
 mutant mice do not produce any
mature B and T lymphocytes (37). Therefore, the A-LAKs
generated from Rag-1
 
2
 
/
 
2
 
 will not contain CTLs or NKT
cells, and thus no cell-mediated cytolysis will be contrib-
uted by these populations. As expected, upon culturing
spleen cells from B6 
 
3 
 
129 Rag-1
 
2
 
/
 
2
 
 mice with rIL-2,
CD3
 
2
 
, TCR-
 
a
 
/
 
b
 
2
 
, and NK1.1
 
1 
 
A-LAKs were detected
by FACS
 
®
 
 and no CD3
 
1
 
 and TCR-
 
a
 
/
 
b
 
1
 
 were present (data
not shown). Our results indicate that RMA/S.CD1.1 but not
RMA/S is resistant to lysis by rIL-2–activated Rag-1
 
2
 
/
 
2
 
NK cells (Fig. 5). We conclude that NK cell cytotoxic ac-
tivity against the NK cell–sensitive RMA/S target cell can
be inhibited by mCD1.1 expression.
 
mCD1.1 Inhibits A-LAK Cytotoxic Activity Generated from
Mouse Strains of Different H-2 Haplotypes. Since CD1 is a
nonpolymorphic class I MHC molecule, this implies that
any NK receptor(s) which may mediate negative regulatory
signal(s) upon mCD1.1 engagement could be conserved in
mice. Thus, mCD1.1 may be able to inhibit the cytotoxic
activities of A-LAKs derived from different inbred mouse
strains. To test this hypothesis, we generated A-LAKs from
two additional mouse strains, CBA/J (H-2k) and NZB/
BinJ (H-2d). The results indicated that the A-LAKs from
these mouse strains exhibit similar patterns of mCD1.1-
Figure 3. Expression of
mCD1.1 renders RMA/S as re-
sistant to day 5 and 6 A-LAKs as
the classical class I MHC–express-
ing RMA cell line. 51Cr-labeled
targets were incubated with
pooled day 5 and 6 B6 A-LAKs
for 4 h. Each data point represents
triplicate determinations, and data
are shown as means 6 SD. All
spontaneous release values were
,17.9%. This experiment was re-
peated three times with similar
results.
Figure 4. The mCD1.1 trans-
fectant of RMA/S is not intrinsi-
cally resistant to cell-mediated
lysis. RMA/S and RMA/S.
CD1.1 cells were grown over-
night at 268C, then 51Cr-labeled
and pulsed with or without 400
mg/ml of NP peptide at 378C for
1 h. The cells were then incu-
bated with CTL clone 3/4 for 4 h
at various E/T ratios in triplicate.
Results are shown as means 6
SD. In all cases, the spontaneous
release values were ,9.4%.
Identical results were obtained in
two additional experiments.487 Chang et al.
mediated inhibition as seen in the B6 A-LAKs (Fig. 6, A
and B). For instance, the day 3 A-LAKs lysed RMA/S and
RMA/S.CD1.1, whereas a significant reduction in lysis of
RMA/S.CD1.1 relative to RMA/S was detected if day 5
and 7 A-LAKs were used as effectors. It is perhaps worth
noting that the patterns of inhibition among these mice are
not exactly identical. In both B6 and NZB/BinJ mice,
RMA/S is highly susceptible to lysis by all A-LAK popula-
tions, and the reduction of RMA/S.CD1.1 lysis becomes
clear in those A-LAKs obtained at later time points (Fig. 2,
and Fig. 6 A). In contrast, A-LAKs derived from CBA/J
show a somewhat different kinetic pattern. The day 3
A-LAKs  have low cytotoxicity against RMA/S, and it only
became strongly observable with day 7 A-LAKs (Fig. 6 B),
whereas RMA/S.CD1.1 remained relatively resistant to
A-LAKs obtained at all of the various culture periods with
rIL-2 (Fig. 6 B). The reasons for the somewhat different ki-
netic inhibition patterns are not clear. Nevertheless, these
results demonstrate that mCD1.1 is able to suppress A-LAK
activities of different mouse strains expressing distinct H-2
haplotypes, consistent with the possibility that a conserved
NK inhibitory receptor(s) for mCD1.1 may exist that is
able to suppress A-LAK cytotoxic activity.
Anti-mCD1.1 mAb, 1B1, Partially Restores the A-LAK
Lysis of RMA/S.CD1.1. The preceding in vitro cyto-
toxic assays suggest that mCD1.1 is capable of negatively
regulating A-LAK cytotoxic activity. To confirm this, we
tested whether the inhibition of lysis of RMA/S.CD1.1
target could be reversed in the presence of an antibody that
recognizes mCD1.1. Consistent with the previous results,
reduction of A-LAK–mediated lysis of RMA/S.CD1.1,
relative to RMA/S, was observed in the absence of any
mAb (Fig. 7). However, with a final concentration of 20
mg/ml of the anti-mCD1.1 mAb, 1B1, lysis of RMA/
S.CD1.1 was partially restored (Fig. 7). This restoration of
lysis is not mediated by antibody-dependent cell-mediated
cytotoxicity, since in the presence of an isotype control
mAb, M1/89.18.7.HK specific for CD45, no restoration of
lysis was detected (Fig. 7). These data indicate that cell sur-
face expression of mCD1.1 is likely to be critical in inhibit-
ing the A-LAK cytotoxic activity. In all attempts with the
1B1 antibody, we were unable to completely restore the
killing of RMA/S.CD1.1 to the same level as that of
RMA/S. The reason for this incomplete restoration of
lysis by 1B1 is not clear. It is perhaps interesting to note
that 1B1 also only partially inhibits peptide-specific and
mCD1.1-restricted CTL lysis (38). It is possible that 1B1
recognizes an epitope that is only partially overlapping with
the putative receptor(s) that mediates the inhibition of
A-LAK lysis.
Figure 5. A-LAKs derived
from 129 3 B6 Rag-12/2 mice
lyse RMA/S, but not the RMA/
S.CD1.1 transfectant. 51Cr-labeled
targets were incubated with Rag-
12/2 A-LAKs at different E/T ra-
tios for 4 h. Each E/T ratio was
used for triplicate determinations,
and the data are expressed as
means 6 SD. The spontaneous
release values were ,9.6%. Simi-
lar results were obtained in three
separate experiments.
Figure 6. Cytotoxicity by A-LAKs generated from NZB/BinJ (A) and
CBA/J mice (B) is inhibited by mCD1.1. The day 3, 5, and 7 A-LAKs
from both strains of mice were incubated with 51Cr-labeled RMA/S (e)
or RMA/S.CD1.1 (s) target cells. Each data point is the mean of tripli-
cate wells 6 SD. Spontaneous release values were ,15%. This experi-
ment was performed twice with effector cells from both mouse strains.
Figure 7. Antibody against mCD1.1 but not CD45 partially restores
day 6 A-LAK cytotoxic activity against RMA/S.CD1.1. 51Cr-labeled
RMA/S.CD1.1 or RMA/S targets were incubated at a 25:1 E/T ratio
with A-LAKs in the presence of 20 mg/ml of 1B1, anti-mCD1.1, or M1/
89.18.7.HK, anti-CD45, for 4 h at 378C. Each mAb treatment was car-
ried out in triplicate, and the percentage of lysis is shown as mean 6 SD.
Spontaneous release values were ,8.6%. This experiment was performed
six times with similar results.488 Regulation of Natural Killer Cell Lysis by mCD1.1
Discussion
In this study, we have shown that A-LAK/NK cytotoxic
function is negatively regulated by mCD1.1. We first ob-
served that mCD1.1 only partially inhibited the cytotoxic-
ity of poly I:C–activated NK cells. There are at least two
possible explanations for this observation: that only a small
fraction of the total NK population expresses the KIR(s)
for mCD1.1, or that only this population expresses the rel-
evant receptor(s) at high enough density to deliver the
inhibitory signal(s). Regardless of the true nature of this
population, it or a subset with similar properties can be de-
tected by consecutively transferring NA-LAKs early in cul-
ture in rIL-2 to generate A-LAKs later in culture. Whether
this protocol actually expands a relevant but small NK sub-
population, or whether it simply induces upregulated ex-
pression of an inhibitory receptor specific for mCD1.1,
remains to be determined.
The mCD1.1 protein is by far the most divergent class I
molecule demonstrated to inhibit NK cell cytotoxic activ-
ity. However, it has been reported that human CD1a, b,
and c do not protect target cells from NK lysis (39). It is
important to note that these group 1 CD1 molecules have
rather different amino acid sequences than the group 2
CD1 molecules, which includes human CD1d, mCD1.1,
and mCD1.2. For instance, the a1 and a2 domains of hu-
man CD1d are more similar to that of mCD1.1 and 1.2
than they are to the other human CD1 molecules (20).
These differences might explain why human CD1a, b, and
c failed to inhibit NK cell cytotoxic function. Therefore, it
will be interesting to determine whether human CD1d also
protects target cells from lysis. Another major difference
between the earlier human CD1 study and ours is that the
NK cells used earlier were isolated from peripheral blood,
and in some instances were further activated by rIL-2 for
only 18 h (39). It is possible that this short-term culturing
condition did not allow the upregulation of an inhibitory
receptor(s) specific for CD1, outgrowth of relevant cell
subpopulations, or other changes that would result in CD1-
mediated protection of target cells.
mCD1 is encoded by two highly related genes resulting
from gene duplication, mCD1.1 and mCD1.2, which are
.95% homologous at the level of amino acid sequences
(17, 18). However, based on the presence of mRNAs, their
expression levels are rather different. For instance, mCD1.1
is highly expressed in all tissues compared with mCD1.2,
except in thymus where both mCD1 are expressed to ap-
proximately the same level (40). In addition, mCD1.2 lacks
a conserved cysteine residue in its a2 domain, which is
presumably important in forming a disulfide bridge in
mCD1.1 and other class I MHC molecules (40). Thus,
mCD1.2 might not be functional. Whether mCD1.2 can
inhibit NK cell cytotoxic activity similar to mCD1.1 re-
mains to be determined. It is reported that B6 mice do not
express mCD1.2 due to a frameshift mutation in exon 4
encoding the a3 domain (41). The significance of this is
not clear, but it raises the possibility that a deficiency in
mCD1.2 expression might influence the expression level of
putative inhibitory receptor(s) for mCD1.1, as can occur
with NK inhibitory receptors specific for classical class I
MHC molecules (42).
The TAP-2–deficient cell line, RMA/S, can present
peptides derived from cytosolic proteins on classical class I
MHC through a TAP-independent pathway (43, 44). Thus,
it can be argued that the protective effect seen in RMA/
S.CD1.1 is actually mediated by classical class I MHC and
mCD1.1 only indirectly. For instance, mCD1.1-derived pep-
tides might be bound to and stabilize the normally empty
and thermally unstable Db and Kb molecules expressed by
RMA/S. This in turn would protect the target cells from
A-LAK lysis. However, this argument is not supported by
the fact that no increase in cell surface expression of Db and
Kb can be detected in the mCD1.1 transfectant (data not
shown). Regulation of NK cell cytotoxicity by human
nonclassical class I HLA-E has been described recently (31,
32). It was shown that HLA-E presentation of leader se-
quences derived from other HLA molecules is critical in
this HLA-E–mediated inhibition, through interaction with
the CD94/NKG2A heterodimer (31, 32). Since murine
nonclassical class I Qa-1b is the murine homologue of
HLA-E, it is possible that the mCD1.1 inhibition of
A-LAK cytotoxic activity is actually mediated by Qa-1b.
However, this interpretation is highly unlikely, since the
leader sequence of mCD1.1 does not contain the necessary
motif to bind Qa-1b. An additional argument against such
interpretations of the data is that an mCD1.1-specific mAb
partially restored the susceptibility of RMA/S.CD1.1 to
NK lysis. This indicated that the suppression was indeed
mediated by intact, cell surface mCD1.1. We have shown
previously that untransfected RMA/S cells do express some
cell surface mCD1 (34). However, the amount of mCD1
expression by these cells is much less than the expression
level in RMA/S.CD1.1 transfectants. In fact, the level of
mCD1.1 expression in RMA/S cells supports a response to
lipoglycan a-galactosylceramide, but it is not sufficient for
stimulating peptide-specific T cells (30), in addition to not
inhibiting NK cell activity. However, it should be noted
that the level of mCD1.1 expression on the RMA/S trans-
fectant is not unphysiologic, and is similar to the level
present on B cells and freshly isolated dendritic cells (41, 45).
mCD1.1 is nonpolymorphic (17, 18), and we observed
that its expression protected RMA/S from lysis by A-LAKs
from a variety of mouse strains. The conserved structure of
mCD1.1 and the broad pattern of A-LAK inhibition sug-
gest the existence of a conserved inhibitory receptor(s) spe-
cific for mCD1.1 expressed by A-LAK cells of the strains of
mice we have tested. It is unlikely that the inhibition is me-
diated by lectin-like NK inhibitory receptors Ly-49A, G,
or C/I, since these molecules are detected on B6 day 3
and 4 A-LAKs as well as A-LAKs obtained later in culture,
and RMA/S.CD1.1 is highly susceptible to lysis by these
A-LAKs (data not shown). Based on the inhibition pattern
of mCD1.1, one would predict that the receptor(s) would
be absent or reduced in expression on day 3 and 4 A-LAKs489 Chang et al.
but present on A-LAKs from later time points. Since no
mAbs specific for other potential inhibitory Ly-49 family
members such as Ly-49B, E, and F have been described,
we do not know the expression pattern of these molecules
on A-LAKs generated at different time points. It remains
possible that Ly-49 members with divergent amino acid se-
quences, such as Ly-49B, might recognize mCD1.1. How-
ever, it has been demonstrated that inhibition of NK func-
tion by class I MHC molecules can be achieved in the
absence of Ly-49 receptor expression (46–48). This is espe-
cially true for NK cells derived from fetal tissues (46–48).
Interestingly, Kumar and colleagues suggest that fetal Ly-492
NK cells might be regulated by nonclassical class I MHC
molecules (47). Nevertheless, the suggestion of a lectin-like
inhibitory receptor for mCD1.1 is rather interesting, espe-
cially since mCD1.1 possesses five potential N-linked gly-
cosylation sites on its extracellular domains (40). With the
recent cloning of murine CD94 and the suggestion of the ex-
istence of murine NKG2 (49), CD94 heterodimers can po-
tentially be the receptor(s) for mCD1.1. However, mAbs
specific for these receptors have to be developed to assess
their involvement in mCD1.1-mediated inhibition. Another
candidate for an mCD1.1-specific inhibitory receptor is
gp49B1, which belongs to the Ig superfamily (50). However,
this inhibitory receptor is expressed on all NK cells, and can
be detected on A-LAKs that have been cultured for 3 d (50).
Thus, it seems unlikely that gp49B1 is the inhibitory receptor
for mCD1.1. At present, the identity of mCD1.1-specific in-
hibitory receptor(s) remains to be determined.
Mass spectrometry and radiolabeling data have shown
that the majority of the material bound to mCD1.1 in nor-
mal cells is a glycosylphosphatidylinositol (51), while CD1
molecules can also bind, as well as present, non–self-anti-
genic glycolipids to NKT cells (29, 30). Therefore, it can
be speculated that mCD1.1 may represent a means by
which NK cells can differentiate self- and non–self-anti-
gens. For instance, mCD1.1 might only suppress NK cell
functions when bound with a self–natural ligand, but not
when antigenic microbial lipoglycan antigens are being
presented. For the best-characterized Ly-49 family mem-
ber, Ly-49A, its interaction with class I MHC molecules
appears to be peptide dependent, but not peptide specific
(52). In contrast, the CD94/NKG2A heterodimer only
recognizes HLA-E in the presence of leader peptides de-
rived from certain HLA products (31, 32). Thus, it is possi-
ble that mCD1.1 can regulate NK cell function in a ligand-
dependent manner, but this remains to be examined.
It is known that the distribution of various inhibitory re-
ceptors is not restricted to NK cells. For example, in addi-
tion to NK cells, the Ly-49 inhibitory receptors are known
to be expressed by subsets of NK1.11CD31 NKT cells and
NK1.12CD31 T cells (53). Upon engagement with class I
MHC, these inhibitory receptors can downregulate the cy-
totoxicity and cytokine production by these T cells (53).
Similar results are demonstrated with human CTLs. For in-
stance, cross-linking of the p58 KIR on CTLs can partially
inhibit their cytotoxic activities (54). We have provided
evidence that mCD1.1 protects target cells from NK cell
lysis, and these results suggest that NK cells may express
a receptor for mCD1.1. It is possible that the putative
mCD1.1-specific inhibitory receptor(s) also has a broader
cellular distribution that includes T cells. Since the nature
of this receptor(s) is not known, this hypothesis cannot be
tested at the present time. However, it is interesting to note
that the pool of mCD1.1-autoreactive T cells can be quite
large. It is estimated that these T cells range from 0.5 to 2%
of the lymphocytes in the spleen, and comprise a much
larger percentage of the T cells in the bone marrow and
liver (55). These lymphocytes are reported to be mCD1-
autoreactive, but how these autoreactive T cells are regu-
lated is not entirely clear. Bendelac and colleagues suggest
that the autoreactivity of these T cells is normally sup-
pressed by MHC-specific inhibitory receptor(s) (41). They
further suggest that loss of negative regulation through
these MHC-specific inhibitor receptor(s) could lead to ac-
tivation of these autoreactive T cells (41). Consistent with
this, the autoreactivity of NKT cells for mCD1 is most
striking when hybridomas made from this population are
analyzed. The hybridomas lose expression of NK1.1, and as
a result of fusion, they also may lose expression of other
NK cell receptors, thereby revealing their reactivity for
self-mCD1. Thus, it is possible that the mCD1.1-specific
inhibitory receptor(s) suggested by our study may also be
originally expressed by these mCD1.1-autoreactive T cells.
The possibility that this putative receptor(s) recognizes
mCD1.1 in a ligand-dependent manner is an attractive
model for suppressing mCD1.1-specific autoreactive T
cells. Therefore, the identification of inhibitory receptor(s)
recognizing mCD1.1 may have relevance in understanding
the regulation of both NK and NKT cell activities.
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